Up­dat­ed: Roche hits the brakes on Alzheimer's tri­als af­ter res­ur­rect­ed drug flunks PhI­II

Is it fi­nal­ly time for Roche to give up on gan­tenerum­ab?

The Swiss phar­ma gi­ant re­vealed that the an­ti-amy­loid drug has failed two Phase III tri­als in ear­ly Alzheimer’s dis­ease, the lat­est in a streak of neg­a­tive read­outs for gan­tenerum­ab. Not on­ly did it miss the pri­ma­ry end­points of slow­ing clin­i­cal de­cline, the lev­el of be­ta-amy­loid re­moval was al­so low­er than ex­pect­ed.

In the wake of the flop, Roche’s Genen­tech sub­sidiary is hit­ting the brakes on SKY­LINE, a sep­a­rate Phase III tri­al that kicked off in March.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER